

CURRICULUM VITAE

Dr Jurjees Hasan MSc., MD, FRCP

Department of Medical Oncology, The Christie, Wilmslow Road, Manchester M20 4BX

GMC REGISTRATION 4784933

PRESENT APPOINTMENTS

Consultant Medical Oncologist, The Christie Hospital NHS Trust

QUALIFICATIONS





- M.D. University of Manchester August 2008
- CCST in Medical Oncology August 2005
- MSc. Medical Oncology, University of Manchester, September 2003
- MRCP (UK) January 1998
- MBBS (Univ. of Health Sciences A.P., India) March 1995

I am a consultant medical oncologist based at a tertiary cancer centre specialising in the treatment of pelvic malignancies, principally gynaecological and colorectal cancers. I am a core member of specialist colorectal cancers multidisciplinary team (MDT), and the medical oncology lead for the MDT. I have an active research interest in clinical trials in colorectal and gynaecological cancers. I have advised NICE on an ad hoc basis over the years and served on NICE panels. From 2010-2016 I served on the NIHR Pharmaceuticals panel. Since 2019 I have been a member of the NICE interventional procedures advisory committee. I have also led cancer peer review inspections of cancer units.

I undertake medico-legal work in my specialist fields.

PUBLICATIONS

1. Hasan J, Jayson GC. VEGF antagonists. *Expert Opin Biol Ther* 2001;1:703-718.
2. Hasan J, Byers R, Jayson GC. Intratumoral microvessel density in human solid tumours. *Br J Cancer* 2002;86:1566-1577.
3. Hasan J, Jayson GC. Oral melphalan as a treatment for platinum-resistant ovarian cancer. *Br J Cancer* 2003;88:1828-1830.
4. Danson S, Middleton MR, O'Byrne KJ, Clemons M, Hasan J, Anderson H, Burt PA, Faivre-Finn C, Stout R, Dowd I, Ashcroft L, Beresford C, Thatcher N. Phase II trial of gemcitabine and carboplatin versus mitomycin, ifosfamide and cisplatin or mitomycin, vinblastine and cisplatin in nonsmall cell carcinoma. *Cancer* 2003;98:542-553.
5. Hasan J, Shnyder SD, Bibby M, Double JA, Bicknell R, Jayson GC. Quantitative angiogenesis assays in vivo. A review. *Angiogenesis* 2004;7:1-16.
6. Hasan J, Jayson GC. VEGF antagonists as anti-cancer agents. *Am J Cancer* 2004;3:229-245.
7. Shnyder SD, Hasan J, Cooper PA, Pilarinou E, Jubb E, Jayson GC, Bibby M. Development of a modified hollow fibre assay for studying agents targeting the tumour vasculature. *Anticancer Research* 2005;25:1889-1894.
8. Hasan J, Ton N, Mullamitha S, Clamp A, McNeilly A, Marshall E, Jayson GC. Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer. *Br J Cancer* 2005;93:647-651.
9. Rosa DD, Clamp A, Mullamitha S, Ton NC, Lau S, Clayton R, Slade RJ, Kitchener HC, Shanks JH, Wilson G, McVey R, Hasan J, Swindell R, Jayson GC. The interval from surgery to chemotherapy in the treatment of advanced epithelial ovarian carcinoma. *Eur J Surg Oncol* 2006;32:588-591.
10. Byrd L, Thistlethwaite FC, Clamp A, Ton C, Hasan J, Jayson GC. Weekly Paclitaxel in the treatment of recurrent ovarian carcinoma. *Eur J Gynecol Oncol* 2007;28:174-178.
11. O'Connor JP, Carano RA, Clamp AR, Ross J, Ho CC, Jackson A, Parker GJ, Rose CJ, Peale FV, Friesenhahn M, Mitchell CL, Watson Y, Roberts C, Hope L, Cheung S, Reslan HB, Go MA, Pacheco GJ, Wu X, Cao TC, Ross S, Buonaccorsi GA, Davies K, Hasan J, Thornton P, Del Puerto O, Ferrara N, van Bruggen N, Jayson GC. Quantifying Antivascular Effects of Monoclonal Antibodies to Vascular Endothelial Growth Factor. *Clin Cancer Res.* 2009;15:6674-6682.
12. Mitchell CL, O'Connor JP, Jackson A, Parker GJ, Roberts C, Watson Y, Cheung S, Davies K, Buonaccorsi GA, Clamp AR, Hasan J, Byrd L, Backen A, Dive C, Jayson GC. Identification of early predictive imaging biomarkers and their relationship to serological angiogenic markers in patients with ovarian cancer with residual disease following cytotoxic therapy. *Ann Oncol* 2010;21:1982-1989
13. Dean E, El-Helw L, Hasan J. Targeted therapies in epithelial ovarian cancer. 2010;3:88-113.

14. Hasan J, Jayson GC. Novel anti-angiogenic therapies in ovarian cancer. *Emerging therapeutic targets in ovarian cancer*; 2011. Springer Science.
15. Griffiths RW, Zee YK, Evans S, Mitchell CL, Kumaran GC, Welch RS, Jayson GC, Clamp AR, Hasan J. Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube. *Int J Gynecol cancer* 2011;21:58-65.
16. Metcalf RL, Fry DJ, Swindell R, McGurk A, Clamp AR, Jayson GC, Hasan J. Thrombosis in ovarian cancer. A case control study. *Br J Cancer*. 2014 Mar 4;110(5):1118-24.
17. Horsley L, Cummings J, Middleton M, Ward T, Backen A, Clamp A, Dawson M, Farmer H, Fisher N, Halbert G, Halford S, Harris A, Hasan J, Hogg P, Kumaran G, Little R, Parker GJ, Potter P, Saunders M, Roberts C, Shaw D, Smith N, Smythe J, Taylor A, Turner H, Watson Y, Dive C, Jayson GC; Cancer Research UK Drug Development Office Phase I clinical trial. A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumours. *Cancer Chemother Pharmacol*. 2013 Dec;72(6):1343-52.
18. Conway AM, Clamp AR, Hasan J, Goonetilleke D, Shore K, Wong LM, Wong J, Jayson G. Accessing cancer services in northwest England: the Chinese population. *Eur J Cancer Care (Engl)*. 2014 Jul;23(4):570-81.
19. Khoja L, Kumaran G, Zee YK, Murukesh N, Swindell R, Saunders MP, Clamp AR, Valle JW, Wilson G, Jayson GC, Hasan J. Evaluation of hypertension and proteinuria as markers of efficacy in antiangiogenic therapy for metastatic colorectal cancer. *J Clin Gastroenterol*. 2014 May-Jun;48(5):430-4.
20. Krebs, MG, Backen A, Gollins S, Chau I, Hasan J, Valle JW, Morris K, Beech J, Ashcroft L, Saunders MP, Dive C. Circulating tumour cell enumeration in a Phase II trial of a four-drug regimen in advanced colorectal cancer. *Clin Colorectal Cancer* 2015. doi:10.1016/j.clcc.2014.12.006
21. Khoja L, McGurk A, O'Hara C, Chow S, Hasan J. Mortality within 30 days following systemic anti-cancer therapy, a review of all cases over a 4 year period in a tertiary cancer centre. *Eur J Cancer*. 2015 Jan;51(2):233-40. doi: 10.1016/j.ejca.2014.11.011. Epub 2014 Dec 11
22. L Khoja, L Horsley, A Heesters, J D Machin, C Mitchell, AR Clamp, GC Jayson, J Hasan. Does clinical trial participation improve outcomes in patients with ovarian cancer? DOI: 10.1136/esmooopen-2016-000057 Published 8 June 2016.
23. Khoja L, Nolan K, Mekki R, Milani A, Mescallado N, Ashcroft L, Hasan J, et al. Improved Survival from Ovarian Cancer in Patients Treated in Phase III Trial Active Cancer Centres in the UK DOI: <http://dx.doi.org/10.1016/j.clon.2016.06.011>
24. Morgan RD, Clamp AR, Hasan J, Mitchell C, Saunders G, Mescallado N, Welch R, Jayson GC. An out-patient dose-intense intravenous cisplatin and oral etoposide regimen for the treatment of advanced platinum-resistant ovarian cancer. *Int J Gynecol Cancer*. 2018;28:448-452. doi:10.1097/IGC.0000000000001194
25. Dean E, Khoja L, Clamp A, Jayson GC, Goonetilleke D, Conway AM, Hasan J. Malignant bowel obstruction in ovarian cancer. *Future Oncol*. 2017 Mar;13(6):513-521. doi: 10.2217/fon-2016-0431. Epub 2017 Jan 18
26. Robert L Metcalf, Eamon Al-Hadithi, Nicholas Hopley, Thomas Henry, Clare Hodgson, Antony McGurk, Wasat Mansoor, and Jurjees Hasan. Characterisation and risk assessment of venous thromboembolism in gastrointestinal cancers. *World J Gastrointest Oncol*. 2017 Sep 15; 9(9): 363–371.
27. Pathak R¹, Wallington M², Saunders C³, Braun M⁴, Mullamitha S⁴, Wilson G⁴, Hasan J⁴, Dodwell D⁵, Bomb M², Saunders M⁴. Rapid Analysis of Outcomes Using the Systemic Anti-Cancer Therapy (SACT) Dataset. *Clin Oncol (R Coll Radiol)*. 2017 Jul;29(7):e134-e136. doi: 10.1016/j.clon.2017.02.011. Epub 2017 Mar 18.
28. Banerjee S, Oza AM, Birrer MJ, Hamilton EP, Hasan J, Leary A, Moore KN, Mackowiak-Matejczyk B, Pikiel J, Ray-Coquard I, Trask P, Lin K, Schuth E, Vaze A, Choi Y, Marsters JC, Maslyar DJ, Lemahieu V, Wang Y, Humke EW, Liu JF. Anti-NAP12b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared to pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized open label phase II trial. *Ann Oncol*. 2018 Feb 1. doi: 10.1093/annonc/mdy023. [Epub ahead of print]
29. Jayson G, Zhou C, Backen A, Horsley L, Marti-Marti F, Shaw D, Mescallado N, Clamp A, Saunders M, Valle J, Mullamitha S, Braun M, Hasan J, McEntee D, Simpson K, Little R, Watson Y, Cheung S, Roberts C, Ashcroft L, Manoharan P, Scherer S, del Puerto O, Jackson A, O'Connor J, Parker G, Dive C Plasma Tie2 is a tumor vascular response biomarker for VEGF inhibitors in metastatic colorectal cancer. *Nat Commun* 9(1):4672. doi: 10.1038/s41467-018-07174-1 (2018)
30. Marti-Marti, Francisca; McGurk, Antony; Alam, Nooreen; Bhatt, Lubna; Braun, Michael S; Hubner, Richard A (0000-0002-7081-8823) ; Mansoor, Was; McBain, C; McNamara, Mairéad G (0000-0002-2272-3678) ; Mullamitha, Saifee A; Saunders, Mark P; Sheikh, Hamid Y; Thistlethwaite, Fiona C (0000-0002-4832-7008) ; Valle, Juan W (0000-0002-1999-0863) ; Wilson, Gregory; Hasan, Jurjees. 30-day mortality associated with systemic anti-cancer therapy (SACT) in gastrointestinal malignancies: The Christie experience. 2018, 29(suppl_5): Ann Oncol
31. Morgan RD, Clamp AR, Hasan J, Mitchell C, Saunders G, Mescallado N, Welch R, Jayson GC. An Outpatient, Dose-Intense, Intravenous Cisplatin and Oral Etoposide Regimen for the Treatment of Advanced, Platinum-Resistant Ovarian Cancer. *Int J Gynecol Cancer*. 2018 Mar;28(3):448-452.
32. Morgan R, Burghel G, Flaum N, Bulman M, Clamp A, Hasan J et al. Prevalence of germline pathogenic BRCA1/2 variants in sequential epithelial ovarian cancer cases. *Journal of Medical Genetics*. 2019 Jan 5.
33. Bond S, Teubner A, Taylor M, ..Hasan J, Mitchell C, Jayson GC, Lal S. A novel discharge pathway for patients with advanced cancer requiring home parenteral nutrition. *J Hum Nutr Diet*. 2019 Apr 21. Doi:10.1111/jhn.12650
34. Morgan RD, Clamp AR, Zhou C, Saunders G, Mescallado N, Welch R, Mitchell C, Hasan J, Jayson GC. Dose-dense cisplatin with gemcitabine for relapsed platinum-resistant ovarian cancer. *International Journal of Gynecologic Cancer* 2019;29:341-345.
35. Morgan RD, Stamatopoulou S, Mescallado N, Saunders G, Welch R, Mitchell C, et al. Screening tool for malignant bowel obstruction in relapsed, metastatic ovarian cancer. *ESMO Open*. 2019; 4(2):e000463.
36. Treasure, T., Farewell, V., Macbeth, F. et al. Pulmonary Metastectomy versus Continued Active Monitoring in Colorectal Cancer (PulMiCC): a multicentre randomised clinical trial. *Trials* 20, 718 (2019). <https://doi.org/10.1186/s13063-019-3837-y>
37. Morgan RD, et. al. Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial. *Gynecologic Oncology*,2020;156:545 - 551 .

38. Flaum N, Morgan R, Burghel GJ et. al. Mainstreaming germline BRCA1/2 testing in non-mucinous epithelial ovarian cancer in the North West of England. *Eur J Human Genet* 2020 Nov;28(11):1541-1547
39. Hall M, Bertelli G, Li L, et al. Role of front-line bevacizumab in advanced ovarian cancer: the OSCAR study. *International Journal of Gynecologic Cancer* 2020;30:213-220.
40. Batchelor T, Hasan J, Macbeth F, Shackcloth M, Treasure T. Randomised Controlled Trial Evidence Questions the Assumption that Pulmonary Metastasectomy Benefits Patients with Colorectal Cancer. *Ann Surg Oncol*. 2021 Jul;28(7):4066-4067. doi: 10.1245/s10434-020-09521-3.
41. Kamposioras, K.; Saunders, M.; Lim, K.H.J.; Marti, K.; Anderson, D.; Cutting, M.; McCool, D.; Connell, J.; Simpson, L.; Hasan, J.; et al. The Impact of Changes in Service Delivery in Patients With Colorectal Cancer During the Initial Phase of the COVID-19 Pandemic. *Clin. Color. Cancer* 2020, 20, e120–e128.
42. Nagy B, Morgan RD, Jayson GC, Mitchell C, Clamp AR, Hasan JH. 822P Comparison of toxicities of PARP inhibitors used in gynaecological cancers observed at a large cancer centre. *Annals of Oncology*. 2020;31:S621-S.
43. Reem D. Mahmood, Robert D. Morgan, Tine Descamps, Claire Mitchell, Jurjees Hasan, Nerissa Mescallado, Lisa Barraclough, Kate Haslett, Jacqueline Livsey, Emma J. Crosbie, Richard J. Edmondson, Gordon C. Jayson, Andrew R. Clamp. Sequential chemotherapy-radiotherapy as adjuvant treatment of high-risk endometrial carcinoma: a retrospective review of the Manchester experience. *European Journal of Gynaecological Oncology*, 2021, 42(4): 673-681 doi:10.31083/j.ejgo4204103
44. Logue CA, Pugh J, Foden P, Mahmood RD, Morgan RD, Mitchell C, Hasan J, Clamp AR, Jayson GC. Psychosexual Morbidity in Women With Ovarian Cancer: Evaluation by Germline BRCA Gene Mutational Status. *Sex Med*. 2022 Feb;10(1):100465. doi: 10.1016/j.esxm.2021.100465. Epub 2021 Dec 15. PMID: 34922303.
45. Morgan RD, Clamp AR, Ryder WDJ, Wheeler C, Buckley E, Truelove J, et al. 731P Multi-maintenance olaparib in relapsed, platinum-sensitive BRCA-mutant high-grade serous ovarian carcinoma (MOLTO): A phase II feasibility study. Vol. 32, *Annals of Oncology*. Elsevier BV; 2021. p. S733-4.
46. Kamposioras, K.; Lim, K.H.J.; Williams, J.; Alani, M.; Barriuso, J.; Collins, J.; Marti, K.; Braun, M.; Mullamitha, S.; Hasan, J.; et al. Modification to Systemic Anticancer Therapy at the Start of the COVID-19 Pandemic and its Overall Impact on Survival Outcomes in Patients with Colorectal Cancer. *Clin. Color. Cancer* 2021, 21, e117–e125.
47. Morgan, R D, Burghel, G J, Flaum, N, Bulman, M, Smith, P, Clamp, A R, Hasan, J, Mitchell, C L, Salih, Z, Woodward, E R, Lalloo, F, Crosbie, E J, Edmondson, R J, Wallace, A J, Jayson, G C, Evans, D G R. BRCA1/2 in non-mucinous epithelial ovarian cancer: tumour with or without germline testing? *British Journal of Cancer*. 2022 Mar 8
48. Morgan RD, Burghel GJ, Flaum N, Bulman M, Smith P, Clamp AR, et al. Predicting the likelihood of a BRCA1/2 pathogenic variant being somatic by testing only tumour DNA in non-mucinous high-grade epithelial ovarian cancer. *Journal of Clinical Pathology*. BMJ; 2022.
49. Wight RKK, Murphy AD, Bower J, Morgan RD, Flanagan L, Maycock S, et al. Malignant bowel obstruction in advanced ovarian cancer: A retrospective analysis of patients supported with parenteral nutrition. *Annals of Oncology*. 2022 Jun;33:S400-S. PubMed PMID: WOS:000814982500044.
50. Kopczynka M, Teubner A, Abraham A, Hasan J, et. al. Parenteral Nutrition in Patients with Advanced Cancer: Quality Outcomes from a Centralized Model of Care Delivery. *Nutrients* 2022, 14(16), 3379; <https://doi.org/10.3390/nu14163379>
51. Lim KHJ, Ntellas P, Anderson D, Simpson L, Braun M, Adamou M, Barriuso J, Dadouli K, Connell J, Williams J, Germetaki T, Lehwald D, Fitzpatrick N, Cutting M, McCool D, Hasan J, Mullamitha S, Marti K, Saunders M, Kamposioras K. The Mental Health Burden of Patients with Colorectal Cancer Receiving Care during the COVID-19 Pandemic: Results of the PICO-SM Study. *Cancers*. 2023; 15(4):1226. <https://doi.org/10.3390/cancers15041226>.
52. Robert D. Morgan, Andrew R. Clamp, Daniel J. White, Marcus Price, George J. Burghel, W. David J. Ryder, Reem D. Mahmood, Alexander D. Murphy, Jurjees Hasan, Claire L. Mitchell, Zena Salih, Chelsey Wheeler, Emma Buckley, Joanna Truelove, Georgia King, Yasmina Ainaoui, Sanjeev S. Bhaskar, Joseph Shaw, D. Gareth R. Evans, Bedirhan Kilerci, Simon P. Pearce, Ged Brady, Caroline Dive, James P.B. O'Connor, Andrew J. Wallace, Dominic G. Rothwell, Richard J. Edmondson, Gordon C. Jayson; Multi-maintenance olaparib therapy in relapsed, germline BRCA1/2-mutant high-grade serous ovarian cancer (MOLTO): a phase II trial. *Clin Cancer Res* 2023; <https://doi.org/10.1158/1078-0432.CCR-22-3282>